· Event impact
Zymeworks to Acquire Theravance Biopharma for $929 Million
Transmission path
Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets.
Market mechanism
Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets.
Extended read
Zymeworks (ZYME) is expanding its portfolio into respiratory care with the acquisition of Theravance Biopharma (TBPH). The deal is notable for its financing structure, utilizing a $350 million note from OMERS, which preserves Zymeworks' cash for its oncology pipeline. The acquisition provides Zymeworks with an immediate revenue stream from YUPELRI, a nebulized LAMA for COPD, marking a transition for the company toward a commercial-stage entity.
Exposed assets
TBPH · ZYME
Continuous event tracking, options routing, and portfolio overlap for this event and the assumptions it moves live inside Market Ontology. Start a trial →